Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial.


Journal Article

The authors assessed the comparative effectiveness of torsemide versus furosemide in the PROTECT trial.The authors assessed the relationship between loop diuretic at discharge and death or cardiovascular/renal hospitalization within 30 days, and death through 150 days postdischarge using inverse probability weighting.Out of 1004 patients, 83.5% received furosemide and 16.5% torsemide. Torsemide patients had higher blood urea nitrogen, and more in-hospital worsening heart failure. Following adjustment, torsemide was associated with similar 30-day outcomes compared with furosemide (p = 0.93), but remained associated with increased 150-day death (hazard ratio: 2.26; 95% CI: 1.40-3.66; p < 0.001).Patients treated with torsemide had features of greater disease severity, similar 30-day outcomes but increased 150-day mortality. Prospective randomized trials are needed to investigate the effect of torsemide versus furosemide.

Full Text

Duke Authors

Cited Authors

  • Mentz, RJ; Velazquez, EJ; Metra, M; McKendry, C; Chiswell, K; Fiuzat, M; Givertz, MM; Voors, AA; Teerlink, JR; O'Connor, CM

Published Date

  • September 25, 2015

Published In

Volume / Issue

  • 11 / 5

Start / End Page

  • 585 - 595

PubMed ID

  • 26403536

Pubmed Central ID

  • 26403536

Electronic International Standard Serial Number (EISSN)

  • 1744-8298

International Standard Serial Number (ISSN)

  • 1479-6678

Digital Object Identifier (DOI)

  • 10.2217/fca.15.56


  • eng